Search

Your search keyword '"Boyd, Jeff"' showing total 666 results
Start Over Author "Boyd, Jeff"
666 results on '"Boyd, Jeff"'

102. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer

Author

Boyd, Jeff, Sonoda, Yukio, Federici, Mark G., Bogomolniy, Faina, Rhei, Esther, Maresco, Diane L., Saigo, Patricia E., Almadrones, Lois A., Barakat, Richard R., Brown, Carol L., Chi, Dennis S., Curtin, John P., Poynor, Elizabeth A., and Hoskins, William J.

Published
2000

116. Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping

Author

Ellis Nathan A, Norton Larry, Friedman Eitan, Klein Robert J, Lautenberger James A, Kirchhoff Tomas, Eskin Eleazar, Stefanov Stefan A, Satagopan Jaya, Struewing Jeffery P, Lohmueller Kirk E, Gold Bert, Olshen Adam B, Viale Agnes, Lee Catherine S, Borgen Patrick I, Clark Andrew G, Offit Kenneth, and Boyd Jeff

Subjects
Genetics, QH426-470
Abstract

Abstract Background Genetic isolates such as the Ashkenazi Jews (AJ) potentially offer advantages in mapping novel loci in whole genome disease association studies. To analyze patterns of genetic variation in AJ, genotypes of 101 healthy individuals were determined using the Affymetrix EAv3 500 K SNP array and compared to 60 CEPH-derived HapMap (CEU) individuals. 435,632 SNPs overlapped and met annotation criteria in the two groups. Results A small but significant global difference in allele frequencies between AJ and CEU was demonstrated by a mean FST of 0.009 (P < 0.001); large regions that differed were found on chromosomes 2 and 6. Haplotype blocks inferred from pairwise linkage disequilibrium (LD) statistics (Haploview) as well as by expectation-maximization haplotype phase inference (HAP) showed a greater number of haplotype blocks in AJ compared to CEU by Haploview (50,397 vs. 44,169) or by HAP (59,269 vs. 54,457). Average haplotype blocks were smaller in AJ compared to CEU (e.g., 36.8 kb vs. 40.5 kb HAP). Analysis of global patterns of local LD decay for closely-spaced SNPs in CEU demonstrated more LD, while for SNPs further apart, LD was slightly greater in the AJ. A likelihood ratio approach showed that runs of homozygous SNPs were approximately 20% longer in AJ. A principal components analysis was sufficient to completely resolve the CEU from the AJ. Conclusion LD in the AJ versus was lower than expected by some measures and higher by others. Any putative advantage in whole genome association mapping using the AJ population will be highly dependent on regional LD structure.

Published
2008
Full Text
View/download PDF

118. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model

Author

Behbakht, Kian, Benjamin, Ivor, Hsiu-Chiang Chiu, Eck, Stephen L., Van Deerlin, Peter G., Rubin, Stephen C., and Boyd, Jeff

Subjects
Ovarian cancer -- Care and treatment, Gene therapy -- Methods, Adenoviruses -- Health aspects, Health
Abstract

An adenovirus with the herpes simplex virus gene may be used to infect ovarian cancer cells to inhibit or even stop their reproduction. Researchers studied the effect of an adenovirus with the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment on laboratory samples of human ovarian cancer cells and on immunodeficient mice injected with human ovarian cancer cells. Ovarian cancers exposed to the adenovirus were more susceptible to treatment with ganciclovir. Mice treated with adenovirus and ganciclovir had lower tumor burdens and no abdominal tumors.

Published
1996

119. Expression and mutational analysis of P53 in stage IB and IIA cervical cancers

Author

Benjamin, Ivor, Saigo, Patricia, Finstad, Connie, Takahashi, Hiroyuki, Federici, Mark, Rubin, Stephen C., and Boyd, Jeff

Subjects
Tumor suppressor genes -- Physiological aspects, Cervical cancer -- Genetic aspects, Health
Abstract

Overproduction of the p53 protein may indicate mutation of the P53 gene in cervical cancer. Mutation of the P53 gene has been associated with development of certain cancers. Researchers reviewed the medical records and examined tissue samples of 132 cervical cancer patients who underwent radical hysterectomy. Small amounts of p53 protein overexpression were found in cervical cancer cells, yet mutation within exons 4 to 10 of the P53 gene were infrequent. Although overexpression of p53 may be found in cervical cancer, it does not predict P53 mutation.

Published
1996

121. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero

Author

Boyd, Jeff, Takahashi, Hiroyuki, Waggoner, Steven E., Jones, Lovell A., Hajek, Richard A., Wharton, J. Taylor, Liu, Fu-shing, Fujino, Takafumi, Barrett, J. Carl, and McLachlan, John A.

Subjects
Adenocarcinoma -- Physiological aspects, Cancer -- Molecular aspects, Vaginal cancer -- Physiological aspects, Cervical cancer -- Physiological aspects, Health
Published
1996

123. Molecular basis of endometrial cancer

Author

Berchuck, Andrew and Boyd, Jeff

Subjects
Endometrial cancer -- Development and progression, Oncogenes -- Physiological aspects, Tumor suppressor genes -- Physiological aspects, Cancer -- Molecular aspects, Health
Published
1995

125. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma

Author

King, Stephanie A., Adas, Amy A., LiVolsi, Virginia A., Takahashi, Hiroyuki, Behbakht, Kian, McGovern, Patricia, Benjamin, Ivor, Rubin, Stephen C., and Boyd, Jeff

Subjects
Uterine cancer -- Genetic aspects, Tumor suppressor genes -- Physiological aspects, Gene expression -- Abnormalities, Health
Abstract

Background. The status of p53 protein expression was determined by immunohistochemistry and correlated with genetic analysis and clinical outcome in patients with uterine papillary serous carcinoma (UPSC). Methods. Twenty-two patients with UPSC were identified and immunohistochemical staining of p53 protein was performed. Staining was analyzed by quantitating nuclear reactivity in 500 randomly counted cells per specimen. DNA analysis was performed on the tumors using single-strand conformation polymorphism (SSCP) analysis of exons 4-10 of the p53 gene, followed by DNA sequencing of all variants. Clinical data and patient status were ascertained from chart reviews. Results. Sixteen of the 22 (73%) tumors were scored as p53-overexpressing as determined by immunohistochemical analysis. Patients whose tumors overexpressed p53 had a statistically significant shorter survival than those whose tumors did not (P < 0.022). DNA analysis of the 22 tumors revealed five with mutations of the p53 gene. Only three of these mutations were observed in tumors that overexpressed p53. Conclusions. A relatively large percentage of UPSC tumors exhibited high p53 immunoreactivity. Overexpression is correlated with poor prognosis. Positive immunohistochemistry for p53 protein in UPSC is not necessarily indicative of a genetic mutation. Cancer 1995; 75: 2700-5. Key words: p53 overexpression, uterine papillary serous carcinoma, genetic mutation, tumor suppressor gene.

Published
1995

126. Loss of heterozygosity on chromosome 17q11-21 in cancer of women who have both breast and ovarian cancer

Author

Schildkraut, Joellen M., Collins, N. Keith, Dents, Georgette A., Tucker, J. Allen, Barrett, J. Carl, Berchuck, Andrew, and Boyd, Jeff

Subjects
Ovarian cancer -- Genetic aspects, Breast cancer -- Genetic aspects, Genetic screening -- Usage, Health
Abstract

Inherited abnormalities of the BRCA1 gene appear to be involved in some cases where women develop both breast and ovarian cancer independently. The BRCA1 gene is believed to be an important tumor suppressor gene, but at the time of this investigation, its chromosome was known, but not its precise location. Only indirect investigation of abnormalities within regions of its chromosome could be carried out. Its location has since been pinpointed. Cancerous and normal tissue samples were analyzed from 29 women who developed primary cancers of both breast and ovary. DNA analysis revealed abnormalities of the chromosome containing BRCA1 in 46% of breast cancers, 78% of ovarian cancers, and 38% of both cancers. In all cases where the chromosome was abnormal in both cancers, the same strand of the pair was affected. These cases also tended to be among younger women. These women seem more likely to have an inherited genetic defect.

Published
1995

130. BRCA1-mediated repression of select X chromosome genes

Author

Ropers H Hilger, Liu Edison T, Nuber Ulrike A, Sotiriou Christos, Aprelikova Olga, Chandramouli Gadisetti VR, Jazaeri Amir A, Yee Cindy J, Boyd Jeff, and Barrett J Carl

Subjects
Medicine
Abstract

Abstract Recently BRCA1 has been implicated in the regulation of gene expression from the X chromosome. In this study the influence of BRCA1 on expression of X chromosome genes was investigated. Complementary DNA microarrays were used to compare the expression levels of X chromosome genes in 18 BRCA1-associated ovarian cancers to those of the 13 "BRCA1-like" and 14 "BRCA2-like" sporadic tumors (as defined by previously reported expression profiling). Significance was determined using parametric statistics with P < 0.005 as a cutoff. Forty of 178 total X-chromosome transcripts were differentially expressed between the BRCA1-associated tumors and sporadic cancers with a BRCA2-like molecular profile. Thirty of these 40 genes showed higher mean expression in the BRCA1-associated samples including all 11 transcripts that mapped to Xp11. In contrast, four of 178 total X chromosome transcripts showed significant differential expression between BRCA1-associated and sporadic tumors with a BRCA1-like molecular profile. All four mapped to Xp11 and showed higher mean expression in BRCA1-associated tumors. Re-expression of BRCA1 in HCC1937 BRCA1-deficient breast cancer cell resulted in the repression of 21 transcripts. Eleven of the 21 (54.5%) transcripts mapped to Xp11. However, there was no significant overlap between these Xp11 genes and those found to be differentially expressed between BRCA1-associated and sporadic ovarian cancer samples. These results demonstrate that BRCA1 mediates the repression of several X chromosome genes, many of which map to the Xp11 locus.

Published
2004
Full Text
View/download PDF

131. Mutations of the Ki-ras oncogene in endometrial carcinoma

Author

Ignar-Trowbridge, Diane, Risinger, John I., Dent, Gerogette A., Kohler, Matthew, Berchuck, Andrew, McLachlan, John A., and Boyd, Jeff

Subjects
Endometrial cancer -- Genetic aspects, Ras genes -- Physiological aspects, Polymerase chain reaction -- Usage, Health
Published
1992

132. The MD CaREs initiative: Tailoring oncology education to ethnically and culturally diverse students.

Author

Diaz, Zuanel, primary, Lupi, Carla, additional, Vargas Madueno, Fernando Manuel, additional, Roller, Barbra A., additional, Brewster, Cheryl, additional, Wells, Alan, additional, Ordonez, Jessica, additional, Suarez, Deborah, additional, Paez, Michael, additional, Boyd, Jeff, additional, Runowicz, Carolyn D., additional, and Villalona-Calero, Miguel Angel, additional

Published
2018
Full Text
View/download PDF

137. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer

Author

Eritja, Núria, primary, Chen, Bo-Juen, additional, Rodríguez-Barrueco, Ruth, additional, Santacana, Maria, additional, Gatius, Sònia, additional, Vidal, August, additional, Martí, Maria Dolores, additional, Ponce, Jordi, additional, Bergadà, Laura, additional, Yeramian, Andree, additional, Encinas, Mario, additional, Ribera, Joan, additional, Reventós, Jaume, additional, Boyd, Jeff, additional, Villanueva, Alberto, additional, Matias-Guiu, Xavier, additional, Dolcet, Xavier, additional, and Llobet-Navàs, David, additional

Published
2017
Full Text
View/download PDF

141. Focused abdominal ultrasound for blunt trauma in an emergency department without advanced imaging or on-site surgical capability

Author

Shuster, Michael, Abu-Laban, Riyad B., Boyd, Jeff, Gauthier, Charles, Mergler, Sandra, Shepherd, Lance, and Turner, Chris

Subjects
Workers' compensation, Health, Health care industry, Science and technology
Abstract

ABSTRACT Objectives: To determine whether focused abdominal sonogram for trauma (FAST) in a rural hospital provides information that prompts immediate transfer to a tertiary care facility for patients with blunt [...]

Published
2004

142. A Phase II Trial of Erlotinib in Patients with Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus

Author

Ilson, David H., Kelsen, David, Shah, Manish, Schwartz, Gary, Levine, Douglas A., Boyd, Jeff, Capanu, Marinela, Miron, Benjamin, and Klimstra, David

Subjects
Male, Esophageal Neoplasms, Antineoplastic Agents, Adenocarcinoma, Middle Aged, Article, ErbB Receptors, Erlotinib Hydrochloride, Mutation, Retreatment, Carcinoma, Squamous Cell, Quinazolines, Humans, Female, Aged
Abstract

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer.Thirty patients with measurable, metastatic cancer of the esophageal and gastroesophageal junction received 150 mg erlotinib daily. EGFR-negative tumors (6 patients; 20%) and EGFR-over expressing tumors (24 patients; 80%) were treated. Most patients were men (70%) with adenocarcinoma (57%) and had received previous chemotherapy (97%).Two partial responses were observe d in the EGFR-positive cohort (2 of 24 patients; 8%), and no responses were observed in the EGFR-negative cohort (0 of 6 patients). Reponses were limited to patients who had squamous cell carcinoma (2 of 13 patients; 15%; response duration, 5.5-7 months). The time to tumor progression was longer in patients who had squamous cell carcinoma (3.3 months; range, 1-24 months) compared with patients who had adenocarcinoma (1.6 months; range, 1-6 months; P = .026). Therapy was tolerable with the expected toxicity of skin rash (grade 1-2, 67%; grade 3, 10%).Erlotinib had limited activity in patients with esophageal cancer, and responses and some protracted stable disease were observed in those with squamous cell carcinoma. Efficacy according to EGFR status could not be assessed given the rarity of EGFR-negative tumors. The current results indicated that further evaluation of this agent in squamous cell carcinoma is warranted. Cancer 2011. © 2010 American Cancer Society.

Published
2010

148. Classification of Ovarian Cancer: A Genomic Analysis

Author

Stany, Michael P., primary, Bonome, Tomas, additional, Wamunyokoli, Fred, additional, Zorn, Kristen, additional, Ozbun, Laurent, additional, Park, Dong-Choon, additional, Hao, Ke, additional, Boyd, Jeff, additional, Sood, Anil K., additional, Gershenson, David M., additional, Berkowitz, Ross S., additional, Mok, Samuel C., additional, and Birrer, Michael J., additional

Full Text
View/download PDF

150. A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer

Author

Hu, Xiaowen, primary, Feng, Yi, additional, Zhang, Dongmei, additional, Zhao, Sihai D., additional, Hu, Zhongyi, additional, Greshock, Joel, additional, Zhang, Youyou, additional, Yang, Lu, additional, Zhong, Xiaomin, additional, Wang, Li-Ping, additional, Jean, Stephanie, additional, Li, Chunsheng, additional, Huang, Qihong, additional, Katsaros, Dionyssios, additional, Montone, Kathleen T., additional, Tanyi, Janos L., additional, Lu, Yiling, additional, Boyd, Jeff, additional, Nathanson, Katherine L., additional, Li, Hongzhe, additional, Mills, Gordon B., additional, and Zhang, Lin, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results